The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Odronextamab receives EC approval for adult patients with R/R FL and DLBCL
On August 26, 2024, it was announced that the European Commission (EC) has approved odronextamab, a CD20xCD3 bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who progress after ≥2 lines of systemic therapy, including a chimeric antigen receptor (CAR) T-cell therapy. This announcement is based on key results from the ELM-1 (NCT02290951) and ELM-2 (NCT03888105) clinical trials, where odronextamab demonstrated robust, durable response rates and an acceptable safety profile in adults with R/R FL or R/R DLBCL. Odronextamab previously received a positive CHMP opinion from the European Medicines Agency for the treatment of patients with R/R FL and R/R DLBCL.
ELM-1 and ELM-2 trials1
ELM-1 is an ongoing multicenter, open-label, phase I trial investigating the safety and tolerability of odronextamab in patients with CD20+ B-cell malignancies who have undergone prior treatment with CD20-directed antibody therapy, including a cohort of patients who have progressed following CAR T-cell therapy.
- In 60 patients with R/R DLBCL, the objective response rate (ORR) in those who had progressed after CAR T-cell therapy was 48%, with 32% achieving a complete response (CR).
- Among responders (n = 29), the median duration of response (DoR) was 15 months.
ELM-2 is an ongoing, open-label, multicenter, pivotal phase II trial investigating the efficacy of odronextamab in adult patients with B-cell non-Hodgkin's lymphoma (B-NHL). The primary endpoint is ORR according to the Lugano Classification, as assessed by an independent review committee (IRC), and secondary endpoints include CR, progression-free survival, overall survival, and DoR.
- In 128 patients with R/R FL, ORR was 80%, with 73% achieving a CR.
- In those achieving CR, the median DoR was 25 months.
- In 127 patients with R/R DLBCL, ORR in CAR T-cell therapy naïve patients was 52%, with 31% achieving a CR.
- In those achieving CR, the median DoR was 18 months.
The most common adverse reactions were cytokine release syndrome (54%), neutropenia (41%), pyrexia (39%), anemia (38%), thrombocytopenia (27%), diarrhea (24%), and COVID-19 (22%).
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
